The stock's fall snapped a three-day winning streak.

Analysts are calling for 25% top-line growth from Intuitive Surgical this year, to be followed by 15% and 17% revenue growth ...

Vertex Pharmaceuticals Inc. closed 10.29% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, ...

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 9% of the investors ...

Investing at least part of the initial $1,000 in an artificial intelligence (AI) stock is a smart move. Despite impressive ...

Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals: 2025 TIME100 Most Influential CompaniesBoston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR ...